Choice of Cell Substrate for Biological Products

  • A. J. Beale
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 118)


The methods at present adopted for the control of the substrate for production of modified live virus vaccines are well established. They involve maintaining colonies of chickens, ducks or rabbits which are the source of primary cells for making such vaccines. These colonies are regularly monitored to exclude infections. The use of human diploid cell lines like WI38 and MRC5 are now internationally accepted as satisfactory substrates for these vaccines and bring the benefits of a defined seed system to the cell substrates as well as to the virus seed. These benefits are consistency and stability; and the ability to use a pretested seed.


Sendai Virus Cell Substrate Oral Poliovirus Vaccine Monkey Kidney Cell Hamster Cheek Pouch 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Capstick P.B., Garland A.J., Chapman W.G., et al. Production of foot and mouth disease virus antigen from BHK 21 clone 13 cells grown and infected in Deep Suspension Cultures. Nature 205:1135–1136, 1965.PubMedCrossRefGoogle Scholar
  2. 2.
    Keeble S.A. and Heymann C.S.. Effect of ß-Propiolactone and Thiomersal on Growth of B.H.K. cells in the Hamster Cheek Pouch. Nature 208:1125–1126, 1965.PubMedCrossRefGoogle Scholar
  3. 3.
    Report. Committee on Tissue Culture Viruses and Vaccines. Continuously cultured tissue cells and Viral Vaccines. Science 139:15–20, 1963.CrossRefGoogle Scholar
  4. 4.
    Pirquet C.F., and Schick B. Serum Sickness. Translated by Bela Schick. Wiliams Wilkins, Baltimore, 1951.Google Scholar
  5. 5.
    Hull R.N., Minner J.R. and Mascoli G.C New agents recovered from tissue cultures of monkey kidney cells. III. Recovery of additional agents both from cultures of monkey kidney tissues and directly from tissues and excreta. American Journal of Hygiene 68: 31–44, 1959.Google Scholar
  6. 6.
    Stones P.B. Production and control of live oral poliovirus vaccine in WI-38 human diploid cells. Joint WHO/IABS Symposium on the standardization of cell substrates for the production of virus vaccines, Geneva, Dec. 1976. Develop. biol. Standard., 37: 251–253. S. Karger, Basel 1977.Google Scholar
  7. 7.
    Christofinis G.J. and Finter N.B. The preparation of Interferon from lymphoblastoid cell lines. Proceedings of Symposium. Preparation, Standardization and clinical use of Interferon. Zagreb, June 8–9, 1977.Google Scholar
  8. 8.
    Pritchett R., Pedersen M. and Kieff E. Complexity of EBV homologous DNA in continuous lymphoblastoid cell lines. Virology 74:227–231. 1976.CrossRefGoogle Scholar
  9. 9.
    Nilsson K., Giovanella B.C., Stehlin F.S. and Klein J. Tumorgenicity of human hematropoietic cell lines in Athymic mice. Inst. of Cancer, 19:337–344, 1977.CrossRefGoogle Scholar
  10. 10.
    Fantes K.H. Workshop on Clinical Trials with Interferon. National Institute of Allergy and Infectious Diseases and National Cancer Institute, Bethesda. March 21–23, 1978.Google Scholar
  11. 11.
    Hughes M., Thomson, R.O., Knight P., and Stephen J. The Immunopurification of Tetanus Toxoid. J. Applied Bacteriology 37:603–621, 1974.CrossRefGoogle Scholar
  12. 12.
    Beale, A.J. D antigen content in poliovaccine as a measure of potency. Lancet 2:1166, 1961.Google Scholar
  13. 13.
    Salk J., Cohen H., Fillastre, et al. Killed poliovirus antigen titration in humans. Developments in Biological Standardization: Standardization and use of vaccines in the developing countries. Proceedings 15th International congress, April 1978. International Association of Biological Standardization (in press).Google Scholar
  14. 14.
    van Wezel A.L., van Steenis G., Hannick Ch.A. and Cohen H. Developments in Biological Standardization: Standardization and use of vaccines in the developing countries. Proceedings 15th International Congress, April 1978. International Association of Biological Standardization (in press).Google Scholar
  15. 15.
    Pereira H.G., Valentine R.C., and Russell W.C. Crystallization of an Adenovirus Protein (The Hexon). Nature, 219:946–947, 1968.PubMedCrossRefGoogle Scholar
  16. 16.
    Mautner V. and Pereira H.G. Crystallization of a second adenovirus Protein (the Fibre). Nature, 230:456–457, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    Haase A.T., Mautner V. and Pereira H.G. The immugenicity of adenovirus type 5 Structural proteins. Journal Immunology, 108: 483–485, 1972.Google Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • A. J. Beale
    • 1
  1. 1.The Wellcome Research LaboratoriesBeckenham, KentEngland

Personalised recommendations